Business
SPEC: Net loss widened as SpectraCure advanced clinical trials, with new funding needed by mid-2025
SPEC: Net loss widened as SpectraCure advanced clinical trials, with new funding needed by mid-2025
About this update from Spectracure Ab
SpectraCure reported a wider full-year net loss and declining cash reserves as it advanced clinical studies for its Q-PRO® prostate cancer system, with positive early results and new global partnerships. Additional funding will be needed by summer 2025.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.